The effect of @entity1363 administration on the pharmacokinetics of XXXX in the @entity35 .

@entity1 @entity109 @entity35 @entity1363 @entity4591
1. The clearance and elimination half-lives for i.v. doses of @entity4591 were determined in 6 groups of 6 male CD @entity35 with no prior treatment, then again following 7 days treatment with graded oral doses of @entity1363 , and finally after 3 i.p. doses of @entity109 . 2. Substantial increases in clearance and decreases in half-lives were observed following @entity109 treatment, demonstrating that @entity4591 provides a reliable index of enzyme induction. 3. After treatment with @entity1363 , maximal induction was seen in animals dosed at 27 or 80 mg/kg per day; an intermediate effect was found with 9 mg/kg per day and no effect at 0.2 and 1.0 mg/kg per day. 4. The results indicate that there is a substantial margin of safety between the proposed @entity1 therapeutic doses (7.5 to 15 mg/day) and the minimum effective dose that leads to enzyme induction in laboratory animals.
